113 related articles for article (PubMed ID: 1835227)
1. [Serotonin as mediator in vomiting reflex: effect of a serotonin3 receptor antagonist in chemotherapy-induced vomiting].
Layer P
Z Gastroenterol; 1991 May; 29(5):265-6. PubMed ID: 1835227
[No Abstract] [Full Text] [Related]
2. Ondansetron to prevent vomiting after cancer chemotherapy.
Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
[No Abstract] [Full Text] [Related]
3. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Egan AP; Taggart JR; Bender CM
Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron to prevent chemotherapy-induced vomiting.
Drug Ther Bull; 1992 Mar; 30(6):21-3. PubMed ID: 1534293
[No Abstract] [Full Text] [Related]
5. Making chemotherapy easier.
Grunberg SM
N Engl J Med; 1990 Mar; 322(12):846-8. PubMed ID: 2137903
[No Abstract] [Full Text] [Related]
6. Ondansetron: a new entity in emesis control.
Graves T
DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
[TBL] [Abstract][Full Text] [Related]
7. [Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
Herrstedt J; Ersbøll J; Dombernowsky P
Ugeskr Laeger; 1991 Apr; 153(18):1292-5. PubMed ID: 1827555
[No Abstract] [Full Text] [Related]
8. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
Schmoll HJ
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
[TBL] [Abstract][Full Text] [Related]
9. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
11. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
[TBL] [Abstract][Full Text] [Related]
12. Fighting nausea in the '90s: more and better anti-emetics can help.
Saphir A
J Natl Cancer Inst; 1997 Sep; 89(17):1252-5. PubMed ID: 9293911
[No Abstract] [Full Text] [Related]
13. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Marty M
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
[TBL] [Abstract][Full Text] [Related]
15. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
Hainsworth JD
Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
[TBL] [Abstract][Full Text] [Related]
16. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
[TBL] [Abstract][Full Text] [Related]
17. [Curative effect of ondansetron on chemically-induced vomiting. Initial results].
Marty M; Le Bonniec M
Presse Med; 1991 Jul 6-13; 20(26):1233. PubMed ID: 1831900
[No Abstract] [Full Text] [Related]
18. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
Gralla R
Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
[No Abstract] [Full Text] [Related]
19. 5HT3-antagonist receptors: their role in drug-induced emesis.
Dieras V; Extra JM; Le Bonniec M; Madelaine I; Espie M; Marty M
Nouv Rev Fr Hematol (1978); 1990; 32(6):449-52. PubMed ID: 1983228
[TBL] [Abstract][Full Text] [Related]
20. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Hartvig P
J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
